Navigation Links
SPX Completes Acquisition of Anhydro
Date:7/21/2010

scussion of certain important factors that relate to forward-looking statements contained in this press release. The word "expect," "believe" and similar expressions may identify forward-looking statements. Although the company believes that the expectations reflected in its forward-looking statements are reasonable, it can give no assurance that such expectations will prove to be correct. Statements in the press release speak only as of the date of this press release, and SPX disclaims any responsibility to update or revise such statements.


'/>"/>
SOURCE SPX Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
6. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
7. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
8. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
9. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
10. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
11. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... , Jan. 22, 2015  ViewRay™, a privately held ... into an exclusive distributor agreement with ITOCHU Corporation (Tokyo ... therapy system for the treatment of cancer in ... system, is the world,s first and only MRI-guided radiation ...
(Date:1/22/2015)... 22, 2015  Uroplasty, Inc. (NASDAQ: UPI ), a ... proprietary products to treat voiding dysfunctions, today reported financial ... 2014.  Global revenue for the Company,s Urgent ... a new quarterly revenue record, as compared to $3.9 ...
(Date:1/22/2015)... , Jan. 22, 2015 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ... focus on Omega-3 therapies for cardiovascular disease and overall health ... Company,s accomplishments in 2014 and its outlook for 2015 from ... Fellow Shareholders, We would like to take this ...
Breaking Medicine Technology:ITOCHU Named the Exclusive Distributor for ViewRay's MRI-Guided Radiation Therapy System in Japan 2Uroplasty Reports Record Revenue in Fiscal Third Quarter 2Uroplasty Reports Record Revenue in Fiscal Third Quarter 3Uroplasty Reports Record Revenue in Fiscal Third Quarter 4Uroplasty Reports Record Revenue in Fiscal Third Quarter 5Uroplasty Reports Record Revenue in Fiscal Third Quarter 6Uroplasty Reports Record Revenue in Fiscal Third Quarter 7Uroplasty Reports Record Revenue in Fiscal Third Quarter 8Uroplasty Reports Record Revenue in Fiscal Third Quarter 9Uroplasty Reports Record Revenue in Fiscal Third Quarter 10Uroplasty Reports Record Revenue in Fiscal Third Quarter 11Uroplasty Reports Record Revenue in Fiscal Third Quarter 12Uroplasty Reports Record Revenue in Fiscal Third Quarter 13Uroplasty Reports Record Revenue in Fiscal Third Quarter 14Uroplasty Reports Record Revenue in Fiscal Third Quarter 15Uroplasty Reports Record Revenue in Fiscal Third Quarter 16Uroplasty Reports Record Revenue in Fiscal Third Quarter 17Uroplasty Reports Record Revenue in Fiscal Third Quarter 18Pivotal Therapeutics: Year in Review and CEO Update 2Pivotal Therapeutics: Year in Review and CEO Update 3Pivotal Therapeutics: Year in Review and CEO Update 4Pivotal Therapeutics: Year in Review and CEO Update 5Pivotal Therapeutics: Year in Review and CEO Update 6Pivotal Therapeutics: Year in Review and CEO Update 7
... 16, 2011 Eli Lilly and Company (NYSE: ... at the 47th Annual Meeting of the American Society of ... 7, 2011, including results from PARAMOUNT, a Phase III study ... advanced nonsquamous non-small cell lung cancer.  PARAMOUNT data will be ...
... May 16, 2011 InspireMD, Inc. (OTCBB: ... MGuard™ mesh protective stent system, will partake in the ... MGuard Prime, InspireMD,s new Cobalt Chromium mesh protective stent ... products feature InspireMD,s MicroNet® Mesh Technology, a potentially superior ...
Cached Medicine Technology:Lilly Oncology to Unveil Data From More Than 30 Studies at ASCO 2InspireMD Promotes MGuard™ at the EuroPCR 2011 Exhibition and Conference in Paris This Week 2InspireMD Promotes MGuard™ at the EuroPCR 2011 Exhibition and Conference in Paris This Week 3InspireMD Promotes MGuard™ at the EuroPCR 2011 Exhibition and Conference in Paris This Week 4
(Date:1/22/2015)... 22, 2015 For over 20 years, Dr. David ... and Vista area has treated just about every type of ... circumstances. And for those same twenty-plus years, the team at ... those injuries with the best possible doctor. With the ...
(Date:1/22/2015)... 2015 A study recently published ... journal Medicine & Science in Sports & Exercise ... help reduce gastrointestinal (GI) problems associated with physical ... in the double-blind, placebo-controlled study took 10 grams ...
(Date:1/22/2015)... 2015 IsoComforter, Inc. has introduced the most ... IsoTube design to treat specific body parts and muscle groups. ... and easy to use patented cold therapy machine with the ... orthopedic and muscle injuries. IsoComforter has become the industry ...
(Date:1/22/2015)... January 22, 2015 EBSCO Information Services ... are expanding their relationship in an effort to further promote ... world. While EBSCO has long made AMA journals available via ... agent for The JAMA Network. , Long known ...
(Date:1/22/2015)... 22, 2015 Compare-autoinsurance.org has released a new blog ... an auto insurance policy . , Some types of ... should check the newly released blog post to see if their ... dangerously damaged vehicles are some of the cars that cannot be ...
Breaking Medicine News(10 mins):Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2Health News:EBSCO Expands Partnership with the American Medical Association 2Health News:EBSCO Expands Partnership with the American Medical Association 3Health News:EBSCO Expands Partnership with the American Medical Association 4Health News:Some Vehicles Cannot Be Covered By An Auto Insurance Policy! 2
... schizophrenia will further confuse patients of the mental illness. ... of the women admitted for psychiatric care in the ... John Fred from Arizona University, says the figures do ... clearly a significant factor. But World Schizophrenia Fellowship head ...
... at Liverpool University have related a link between the length of ... attack at a later age.// They believe the link could ... disease victims at a very early age. , ... be at greatest risk. This is because these boys tend to ...
... a new study a diet high in animal products ... sunlight offers protection. Many studies have suggested a link ... and breast cancer.// An independent researcher based in Chicago, ... variation in breast cancer. Rates are high where the ...
... Swiss researchers found that butterbur extract is an effective ... said,presumably it contains an active biochemical agent,// otherwise it ... that this might react with other medications. ... 154 hayfever patients either butterbur extract tablets or the ...
... developed by a research team from Southampton University,which works by ... the immune cells in the blood.//The lymphoma cells are not ... multiply diversely. ... a sample of tumour cells from a patient, and ...
... in early stages in order to prevent it from ... mammogram as a routine check up, thereby enabling a ... study there has been decreased detection of breast cancer ... at the University of Texas surveyed 300 women with ...
Cached Medicine News:
... part of the Freedom Urinary Collection ... bags, kits, and accessories designed to ... customers. These leg bags are offered ... 100% latex-free soft, textured medical grade ...
... leg bags are part of the ... line of leg bags, kits, and ... needs of our customers. These leg ... and constructed of 100% latex-free soft, ...
... are part of the Freedom Urinary ... leg bags, kits, and accessories designed ... our customers. These leg bags are ... of 100% latex-free soft, textured medical ...
The latex-free, PVC-free Antibacterial Hydro Personal catheter combines two remarkable innovations into one exclusive catheter that delivers an antibacterial agent while providing the virtually frict...
Medicine Products: